Abstract:Jiong Zhang, 1, 2, &ast Juan Chen, 3, &ast Qing Jiang, 1, &ast Rui Feng, 2 Xiaohu Zhao, 2 Haolin Li, 2 Cheng Yang, 2 Xiaoliang Hua 1 1 Department of Urology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing, People's Republic of China; 2 Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, People's Republic of China; 3 The Ministry of Education Key Laboratory of Laboratory Medical Diagnostics, the College of Laboratory Medicine, Chongqing Medical University, Chongqing, 400016, People's Republic of China &astThese authors contributed equally to this work Correspondence: Cheng Yang, Department of Urology, the First Affiliated Hospital of Anhui Medical University, No. 218 Jixi Road, Shushan District, Hefei, 230022, People's Republic of China, Tel +86 0551 6292 3440, Fax +86 551 6363 3742, Email Xiaoliang Hua, Department of Urology, the Second Affiliated Hospital of Chongqing Medical University, No. 74 Linjiang Road, Yuzhong District, Chongqing, 400010, People's Republic of China, Tel\Fax +86 023 6369 3222, Email Background: Resolvin D1 (RvD1), a member of the specialized pro-resolving lipid mediators family, has a potent anti-inflammatory effect and alleviates tissue damage. The purpose of the current research was to study the effect of RvD1 on CP/CPPS and the underlying mechanisms using a mouse model of experimental autoimmune prostatitis (EAP) mice. Materials and Methods: The EAP mouse model was successfully established, and was used to test the therapeutic effect of RvD1. Hematoxylin-eosin staining and dihydroethidium staining were used to evaluate the histological changes and oxidative stress levels of prostate tissues. Chronic pelvic pain was assessed by applying von Frey filaments to the lower abdomen. The superoxide dismutase enzyme and malondialdehyde levels were detected using enzyme-linked immunosorbent assay (ELISA). The levels of inflammation-related cytokines, including IL-1β, IL-6, and TNF-α were detected by ELISA. Results: RvD1 treatment ameliorated prostatic inflammation and the pelvic pain of EAP mice. RvD1 treatment could inhibit activation of the NLRP3 inflammasome and oxidative stress. RvD1 treatment could activate Nrf2/HO-1 signaling in mice with EAP. Blockade of Nrf2/HO-1 signaling abolished the RvD1-mediated inhibition of oxidative stress, NLRP3 inflammasome activation and the anti-inflammatory effect of RvD1 in EAP. Conclusion: RvD1 treatment can reduce inflammatory cell infiltration in prostate tissue and attenuate pelvic pain associated with EAP by inhibiting oxidative stress and NLRP3 inflammasome activation via the Nrf2/HO-1 pathway. These results provide new insights that RvD1 has the potential as an effective agent in the treatment of EAP. Keywords: chronic prostatitis and chronic pelvic pain syndrome, CP/CPPS, resolvin D1, inflammation, NLRP3 inflammasome, oxidative stress Chronic prostatitis, a very common disease of the genitourinary system, affected approximately 35–50% of men in their lifetime. 1–3 Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) is the most common type, accounting for more than 90% of all cases of chronic prostatitis among males under 50 years of age. CP/CPPS is a poorly understood syndrome characterized by perineal or pelvic pain, urinary irritation, psychological issues, and sexual dysfunction without infection, and it negatively affects sperm and quality of life. 1–4 As the etiology of CP/CPPS is still not well understood, available therapeutic options including alpha blockers, anti-inflammatory drugs, physiotherapy, and neuroleptics are far from satisfactory to either patients or physicians. 5,6 Therefore, a new treatment for CP/CPPS and a better understanding of its pathogenesis are urgently needed. Recent studies have shown that the specialized pro-resolving lipid mediators deriving predominantly from ω-3 and ω-6 essential fatty acids, play a vital role in the chronic inflammatory diseases. 7 Resolvin D1 (RvD1) is a specialized pro-resolving lipid mediator that is derived predominantly from docosahexaenoic acid. The potent effects of RvD1 on chronic inflammatory disease have attracted attention in recent years. The anti-inflammatory effects of RvD1 have been verified in multiple inflammatory diseases, including non-alcoholic steatohepatitis, 8 cholestatic liver fibrosis, 9 and rheumatoid arthritis. 10 In addition, RvD1 has an inhibitory effect on oxidative stress and apoptosis, further reducing tissue damage. 11,12 RvD1, as an endogenous met -Abstract Truncated-

Resolvin D2/GPR 18 axis ameliorates pressure overload-induced heart failure by inhibiting pro-inflammatory macrophage polarization

The Anti-Inflammatory Mediator 17(R)-Resolvin D1 Attenuates Pressure Overload-Induced Cardiac Hypertrophy and Fibrosis

Resolvin D1 attenuates Ang II-induced hypertension in mice by inhibiting the proliferation, migration and phenotypic transformation of vascular smooth muscle cells by blocking the RhoA/mitogen-activated protein kinase pathway

Resolvin D2 prevents vascular remodeling, hypercontractility and endothelial dysfunction in obese hypertensive mice through modulation of vascular and proinflammatory factors

Resolvin D2/GPR18 signaling enhances monocytic myeloid-derived suppressor cell function to mitigate abdominal aortic aneurysm formation

Post-treatment with Resolvin D1 attenuates pulmonary hypertension by inhibiting endothelial-to-mesenchymal transition

Resolvin D1 Attenuates Doxorubicin-Induced Cardiotoxicity by Inhibiting Inflammation, Oxidative and Endoplasmic Reticulum Stress

Resolvin D1 protects against sepsis‐induced cardiac injury in mice

The Anti-inflammatory Mediator Resolvin E1 Protects Mice Against Lipopolysaccharide-Induced Heart Injury

Continuous infusion of resolvin D2 in combination with Angiotensin-II show contrary effects on blood pressure and intracardiac artery remodeling

Resolvin D1 Improves the Resolution of Inflammation via Activating NF-κB p50/p50-Mediated Cyclooxygenase-2 Expression in Acute Respiratory Distress Syndrome

Abstract PR099: Resolvin D1 Improves the Resolution of Inflammation Via Activation P50/P50-Mediated Cyclooxygenase-2 Expression in Fibroblasts.

Therapeutic Activity of Resolvin D1 (RvD1) in Murine MASH

An inflammation resolution-promoting intervention prevents atrial fibrillation caused by left ventricular dysfunction

Resolvin D1 Attenuates Inflammation and Pelvic Pain Associated with EAP by Inhibiting Oxidative Stress and NLRP3 Inflammasome Activation via the Nrf2/HO-1 Pathway

Resveratrol prevents ISO-induced myocardial remodeling associated with regulating polarization of macrophages through VEGF-B/AMPK/NF-kB pathway

Resveratrol prevents Ang II-induced cardiac hypertrophy by inhibition of NF-κB signaling

Resolvin D1 (Rvd1) Attenuates In Vitro LPS-Stimulated Inflammation Through Downregulation of miR-155, miR -146, miR -148 and Krupple Like Factor 5

Lung Inflammation Resolution by RvD1 and RvD2 in a Receptor-Dependent Manner

Reduced HMGB 1-Mediated Pathway and Oxidative Stress in Resveratrol-Treated Diabetic Mice: A Possible Mechanism of Cardioprotection of Resveratrol in Diabetes Mellitus

Resolvin E1 Attenuates Inj Ury‐induced Vascular Neointimal Formation by Inhibition of Inflammatory Responses and Vascular Smooth Muscle Cell Migration